New monoclonal antibodies for the treatment of acute lymphoblastic leukemia

摘要: While the majority of pediatric acute lymphoblastic leukemia (ALL) patients can be cured with combination chemotherapy, novel immunotherapies have provided new treatment options for those with relapsed or refractory disease. In adults, ALL remains challenging to treat, with incremental advances delivered by optimization of cytotoxic chemotherapy regimens and supportive care, integration of tyrosine kinase inhibitor therapies for BCR-ABL-positive disease, and the development of novel immunotherapies. Rituximab, in combination with established chemotherapy regimens, reduces relapse in 30%–50% of patients who have CD20-positive disease. In the past decade, antibody-drug conjugates, bispecific antibodies (immune cell engagers), and CAR-T cell therapies utilizing monoclonal antibody (mAb) technology have entered clinical practice, initially presenting important treatment options for patients with …